DDInter1662 DDInter1026
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.
Sertraline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Sertraline {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Sertraline {u} (Compound) binds {v} (Gene) SLC6A4
SLC6A4 {u} (Gene) is bound by {v} (Compound) Fluvoxamine
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Sertraline {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Teniposide
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Sertraline {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Salivary hypersecretion {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Sertraline {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Sertraline {u} (Compound) binds {v} (Gene) SLC6A2
SLC6A2 {u} (Gene) is bound by {v} (Compound) Nefazodone
Nefazodone {u} may lead to a major life threatening interaction when taken with {v} Larotrectinib
Sertraline {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Salivary hypersecretion {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Sertraline {u} (Compound) downregulates {v} (Gene) DLD
DLD {u} (Gene) is downregulated by {v} (Compound) Pimozide
Pimozide {u} may lead to a major life threatening interaction when taken with {v} Larotrectinib
Sertraline {u} (Compound) causes {v} (Side Effect) Hernia
Hernia {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Larotrectinib
Sertraline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Sertraline (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Sertraline (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Fluvoxamine (Compound) and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Sertraline (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Teniposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Sertraline (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Sertraline (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Sertraline (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Nefazodone (Compound) and Nefazodone may lead to a major life threatening interaction when taken with Larotrectinib
Sertraline (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Sertraline (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Pimozide (Compound) and Pimozide may lead to a major life threatening interaction when taken with Larotrectinib
Sertraline (Compound) causes Hernia (Side Effect) and Hernia (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Larotrectinib